User profiles for Hojjat Ahmadzadehfar
 | Prof. Dr. med. Hojjat Ahmadzadehfar, M.Sc.Klinikum Westfalen, Department of Nuclear Medicine, Dortmund Verified email at klinikum-westfalen.de Cited by 9435 |
Theranostics in nuclear medicine practice
…, G Feldmann, H Ahmadzadehfar… - OncoTargets and …, 2017 - Taylor & Francis
The importance of personalized medicine has been growing, mainly due to a more urgent
need to avoid unnecessary and expensive treatments. In nuclear medicine, the theranostic …
need to avoid unnecessary and expensive treatments. In nuclear medicine, the theranostic …
PSMA theranostics: current status and future directions
…, H Jadvar, H Ahmadzadehfar - Molecular …, 2018 - journals.sagepub.com
Prostate-specific membrane antigen (PSMA) is a promising target for imaging diagnostics
and targeted radionuclide therapy (theranostics) of prostate cancer and its metastases. There …
and targeted radionuclide therapy (theranostics) of prostate cancer and its metastases. There …
Radioembolization of liver tumors with yttrium-90 microspheres
H Ahmadzadehfar, HJ Biersack, S Ezziddin - Seminars in nuclear medicine, 2010 - Elsevier
Radioembolization (RE), also termed selective internal radiation therapy (SIRT), has been
gradually introduced to the clinical arsenal of cytoreductive modalities in recent years. There …
gradually introduced to the clinical arsenal of cytoreductive modalities in recent years. There …
German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients
K Rahbar, H Ahmadzadehfar… - Journal of Nuclear …, 2017 - Soc Nuclear Med
177 Lu-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT)
of patients with metastatic castration-resistant prostate cancer (mCRPC). Initiated by the …
of patients with metastatic castration-resistant prostate cancer (mCRPC). Initiated by the …
[PDF][PDF] Survival after yttrium‐90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation
…, C Urigo, A Cappelli, A Vit, H Ahmadzadehfar… - …, 2011 - Wiley Online Library
A multicenter analysis was conducted to evaluate the main prognostic factors driving survival
after radioembolization using yttrium‐90–labeled resin microspheres in patients with …
after radioembolization using yttrium‐90–labeled resin microspheres in patients with …
[HTML][HTML] Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study
H Ahmadzadehfar, K Rahbar, S Kürpig, M Bögemann… - EJNMMI research, 2015 - Springer
Background Radioligand therapy (RLT) with 177 Lu-DKFZ-617 PSMA (Lu-PSMA) (prostate-specific
membrane antigen) is a novel targeted therapy of metastatic prostate cancer. We …
membrane antigen) is a novel targeted therapy of metastatic prostate cancer. We …
[HTML][HTML] Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
H Ahmadzadehfar, E Eppard, S Kürpig, R Fimmers… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Prostate-specific membrane antigen (PSMA) is highly expressed on prostate epithelial cells
and strongly up-regulated in prostate cancer (PC), making it an optimal target for the …
and strongly up-regulated in prostate cancer (PC), making it an optimal target for the …
Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis
…, M Claesener, H Ahmadzadehfar - Journal of Nuclear …, 2016 - Soc Nuclear Med
Radiolabeled prostate-specific membrane antigen (PSMA) ligands represent a true theranostic
concept for diagnosis and therapy in patients with relapsed or metastatic prostate cancer. …
concept for diagnosis and therapy in patients with relapsed or metastatic prostate cancer. …
Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with …
…, CJ Yong-Hing, H Ahmadzadehfar… - Journal of nuclear …, 2014 - Soc Nuclear Med
Outcome analyses for patients with gastroenteropancreatic neuroendocrine tumors (GEP NET)
after peptide receptor radionuclide therapy (PRRT) are still limited, especially with regard …
after peptide receptor radionuclide therapy (PRRT) are still limited, especially with regard …
Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617
H Ahmadzadehfar, S Wegen, A Yordanova… - European journal of …, 2017 - Springer
Purpose Up to 30% of patients with castration-resistant prostate cancer (CRPC) do not show
any response to the first cycle of radioligand therapy (RLT) with [ 177 Lu]Lu-PSMA-617 (Lu-…
any response to the first cycle of radioligand therapy (RLT) with [ 177 Lu]Lu-PSMA-617 (Lu-…